Efficacy and Safety of TF002 in Cutaneous Mastocytosis
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The current study will investigate the effects of TF002 on cutaneous mastocytosis or
cutaneous involvement of systemic mastocytosis as compared to clobetasol proprionate
(positive control) and a general skin care product without active ingredient targeting
mastocytosis (negative control) based on clinical effects on Darier´s signs and the
histological evaluation of mast cell numbers in skin bioptic material.